Velcade is a medicine used to treat certain types of cancer, like multiple myeloma. It works by stopping the body's natural cleanup system, called the proteasome, from breaking down cancer cells. This helps the cancer cells die off. It's given as an injection.
Every report comes from a Lived member, sent anonymously.
Have you tried Velcade (Bortezomib) for Multiple Myeloma?
Bortezomib is an injectable cancer medicine sold under the brand name Velcade and as a generic. A ready-to-use liquid version is sold as Boruzu. It is approved for adults with multiple myeloma, a cancer of plasma cells (the antibody-making white blood cells in the bone marrow), and for adults with mantle cell lymphoma, a type of non-Hodgkin lymphoma. Bortezomib is almost always given as part of a combination. In newly diagnosed multiple myeloma, a common starting regimen pairs it with lenalidomide (an oral myeloma medicine) and dexamethasone (a steroid), a combination often called VRd. An antibody medicine such as daratumumab is frequently added, and people who are candidates usually go on to a stem cell transplant. Bortezomib is also used when myeloma comes back, and as part of longer-term maintenance for some people whose myeloma has high-risk features. For untreated mantle cell lymphoma, it is given with rituximab (an antibody medicine) and a chemotherapy combination. It is also part of an approved regimen with daratumumab (Darzalex Faspro), cyclophosphamide and dexamethasone for newly diagnosed light chain (AL) amyloidosis, a related plasma cell disorder in which abnormal antibody fragments build up in organs such as the heart and kidneys.
Cells constantly make proteins, and they also need to break down proteins that are damaged or no longer needed. Proteasomes are the structures inside cells that do this disposal work. Bortezomib belongs to a group of drugs called proteasome inhibitors: it blocks part of the proteasome's activity, so unwanted proteins accumulate and the signals that keep the cell functioning are thrown out of balance. This disruption can lead the cell to die. In laboratory studies, bortezomib kills many kinds of cancer cells and slows the growth of myeloma. Its effect is not limited to cancer cells, which is why it also causes side effects in healthy tissues, such as the nerves and the bone marrow.
Bortezomib is given by a nurse in a cancer clinic or hospital, either as an injection under the skin or as a quick injection into a vein lasting a few seconds. It is not a pill and is never taken at home. The dose is calculated from body size (body surface area, worked out from height and weight), so it is individual. Treatment is given in cycles. Depending on the regimen, doses are given once or twice a week with at least three days between doses, followed by a rest period that lets blood counts recover before the next cycle. The number of cycles depends on the cancer, the other medicines in the combination and how well treatment is going. Doses are often held, lowered or spaced out further when blood counts drop or nerve symptoms appear, so changes to the schedule are a normal part of treatment rather than a sign that it has failed. The two routes use the same dose, but in a large trial of people with relapsed myeloma, severe nerve damage was less common with injections under the skin (6%) than with injections into a vein (15%). Starting under the skin may be considered for people who already have nerve problems or are at higher risk of them. People with moderate or severe liver problems start at a lower dose. Kidney problems do not require a lower starting dose, and for people on dialysis bortezomib is given after the dialysis session.
Nausea, diarrhea, constipation, vomiting, tiredness, reduced appetite, fever and rash are among the most common side effects. Medicines for nausea or diarrhea and enough fluids help many people manage them, and severe or persistent digestive symptoms should be reported because they can lead to dehydration. Nerve damage in the hands and feet (peripheral neuropathy) is one of the most important side effects. It can feel like numbness, tingling, burning, pain or extra sensitivity, and some people develop weakness. Report new or worsening symptoms early, because lowering the dose, spacing doses further apart or pausing treatment can keep it from becoming severe. In studies, many people's symptoms improved or went away after these changes, but not everyone's did. Bortezomib lowers platelets (which help blood clot) and white blood cells that fight infection. Counts usually dip toward the end of each cycle and recover before the next. Call the care team right away for a fever, chills or other signs of infection, or for unusual bruising, nosebleeds, bleeding gums, or black or bloody stools. Bortezomib can also lower blood pressure, causing dizziness, lightheadedness or fainting; drinking enough fluids helps, and these symptoms are worth reporting. Shingles (a painful, blistering rash caused by reactivation of the chickenpox virus) is more common during treatment. In one large trial, it affected 17% of people who did not take a preventive antiviral medicine and 3% of those who did, which is why care teams often prescribe one. Less common but serious problems include heart failure, lung inflammation, liver injury and a rare clotting disorder that damages small blood vessels. Tell the care team promptly about new or worsening shortness of breath, cough, swelling in the legs, or yellowing of the skin or eyes. A seizure, sudden changes in vision, or severe headache with confusion can signal a rare brain swelling reaction called PRES (posterior reversible encephalopathy syndrome) and needs emergency care.
A few medicines change how much bortezomib reaches the body. Rifampin, an antibiotic used for tuberculosis and some other infections, lowers bortezomib levels by nearly half and can make it less effective, so the combination is avoided. Strong blockers of the same liver enzyme, such as the antifungal ketoconazole, raise bortezomib levels and call for closer watching for side effects. Bring a full list of prescriptions, over-the-counter products and supplements to the care team, since cancer treatment often involves many medicines at once. People who take blood pressure medicines, have fainted before or tend to get dehydrated are more prone to low blood pressure on bortezomib, and their medicines may need adjusting. People who take diabetes pills should check their blood sugar more often, because levels can change. Those with existing heart disease or heart risk factors are monitored more closely. Bortezomib should not be used by people who have had a serious allergic reaction to bortezomib, boron or mannitol (an ingredient in the product). Bortezomib can harm a developing baby. A pregnancy test is done before starting, and women who could become pregnant should use effective contraception during treatment and for seven months after the last dose. Men whose partners could become pregnant should use effective contraception during treatment and for four months after. Breastfeeding is not recommended during treatment or for two months after the last dose. Bortezomib may also affect fertility, which is worth discussing before treatment starts if future children are a consideration. Because fatigue, dizziness and fainting can occur, avoid driving or operating machinery when these symptoms are present.
Treatment means regular clinic visits, often once or twice a week during active cycles, along with frequent blood tests to check blood counts and other labs. Response is tracked with tests that measure the cancer, such as blood and urine tests for myeloma proteins or scans for lymphoma, so the team can judge whether the combination is working and how long to continue. The length of treatment varies with the regimen and goal. The approved combination for previously untreated mantle cell lymphoma runs six three-week cycles, sometimes eight, while the original combination for older adults with newly diagnosed myeloma ran about a year. In that trial, adding bortezomib to the older two-drug combination lengthened median survival from about 43 months to about 56 months. Maintenance schedules can continue longer. If myeloma comes back at least six months after a good response to bortezomib, it can sometimes be used again. Side effects tend to follow the rhythm of the cycles, and many can be managed with supportive medicines and dose changes. Nerve symptoms deserve particular attention over the course of treatment, because early adjustments are what keep them from limiting daily activities such as walking, buttoning clothes or typing.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Velcade (Bortezomib), what you've noticed, or ask the community a question.